secwatch.observer — SEC 8-K summary
======================================

Issuer:     KIORA PHARMACEUTICALS INC (KPRX)
CIK:        0001372514
Form:       8-K
Filed at:   2021-07-26T23:59:59+00:00
Accession:  0001104659-21-095852
Event type: leadership
Sentiment:  neutral
Materiality: 0.70
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Appoints Brian Strem as President & CEO; signs non-binding LOI to acquire Bayon Therapeutics
--------------------------------------------------------------------------------

- Brian M. Strem appointed President and CEO effective July 26, 2021; Franz Obermayr returns to EVP Clinical Development.
- Strem receives $400K annual base salary, target bonus of 50% of base, and option to purchase 100K shares vesting over 3 years.
- EyeGate enters non-binding term sheet to acquire Bayon Therapeutics for closing consideration of 50K shares and earnout up to $7.1M or ~2.2M shares.
- Strem is co-founder of Bayon and owns ~28% equity; transaction subject to definitive agreement and milestone conditions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1372514/000110465921095852/0001104659-21-095852-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1372514/000110465921095852/tm2123169-1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-21-095852

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer